Zacks Investment Research lowered shares of Cogentix Medical (NASDAQ:CGNT) from a hold rating to a sell rating in a research note published on Thursday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

A number of other research analysts have also weighed in on the company. Aegis initiated coverage on Cogentix Medical in a report on Friday, December 1st. They issued a buy rating and a $4.75 price objective on the stock. JMP Securities assumed coverage on Cogentix Medical in a report on Friday, October 6th. They issued an outperform rating and a $5.00 price objective on the stock. Roth Capital assumed coverage on Cogentix Medical in a report on Wednesday, November 8th. They set a buy rating and a $4.00 price target on the stock. Finally, TheStreet upgraded Cogentix Medical from a d+ rating to a c rating in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company’s stock. Cogentix Medical currently has an average rating of Buy and a consensus price target of $4.06.

Cogentix Medical (CGNT) opened at $2.80 on Thursday. The firm has a market capitalization of $170.54, a price-to-earnings ratio of -6.83 and a beta of 0.63. Cogentix Medical has a fifty-two week low of $1.55 and a fifty-two week high of $3.34.

Several hedge funds and other institutional investors have recently bought and sold shares of CGNT. Northern Trust Corp raised its holdings in shares of Cogentix Medical by 0.4% during the 2nd quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after acquiring an additional 326 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Cogentix Medical during the 3rd quarter worth $152,000. Finally, Broadfin Capital LLC raised its holdings in shares of Cogentix Medical by 45.2% during the 2nd quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after acquiring an additional 340,771 shares during the period. Institutional investors and hedge funds own 13.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/cogentix-medical-cgnt-stock-rating-lowered-by-zacks-investment-research/1845768.html.

Cogentix Medical Company Profile

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Get a free copy of the Zacks research report on Cogentix Medical (CGNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.